Anora Group Oyj (ANORA)
Helsinki Exchange · Finland · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 4.095 |
|---|---|
| 52-week range | 2.930 – 4.560 |
| Return, 1 month / 3 months | +2.8% / +11.9% |
| Return, 1 year / 3 years | +48.6% / +19.2% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 26.5% |
| Worst drawdown (1 year) | -25.0% |
| Average daily value traded | 0.17M EUR |
| Dividend yield | 5.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Anora Group is a Nordic producer and marketer of alcoholic beverages, based in Finland. It makes and distributes wines and spirits, including aquavit, vodka and other distilled drinks, and supplies them to retail monopolies, restaurants, bars and other licensed outlets across the Nordic countries and beyond. The company also handles import and distribution of wine and spirits brands for customers in its home markets, combining its own production with a broad portfolio of partner products.
Anora Group Oyj trades under the code ANORA on the Helsinki Exchange in Finland, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Anora Group Oyj (ANORA) trades on the Helsinki Exchange in Finland. It last closed at EUR 4.095 on 22 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 28 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 48.6% and over the last three months it rose 11.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Helsinki Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.8% | ||
| From 52-week high | -10.1% | ||
| Momentum | 83 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 11.9% | ||
| 6-month return | 16.7% | ||
| 12-month return, skipping the last month | 44.7% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.0% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.17M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 68 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.9% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +6.9% |
|---|---|
| 1 month | +2.8% |
| 3 months | +11.9% |
| 6 months | +16.7% |
| 1 year | +48.6% |
| 3 years | +19.2% |
| 5 years | −49.5% |
Signals
| 50-day / 200-day average | 3.874 / 3.697 |
|---|---|
| Golden / death cross (60 days) | Golden, 48 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.093 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Apr 2026 | EUR 0.2400 |
| 16 Apr 2025 | EUR 0.2200 |
| 18 Apr 2024 | EUR 0.2200 |
| 17 Oct 2023 | EUR 0.1100 |
| 20 Apr 2023 | EUR 0.1100 |
| 12 May 2022 | EUR 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Helsinki Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.